Mulligan, Claire PhD; Beghetti, Maurice MD, FESC
From the Research Evaluation Unit (CM), Oxford PharmaGenesis Limited, Oxford, U.K.; and the Pediatric Cardiology Unit (MB), Department of the Child and Adolescent, Children’s University Hospital, Geneva, Switzerland.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (http://journals.lww.com/pccmjournal).
The writing of this article was funded in part by Bayer HealthCare Pharmaceuticals. Dr. Mulligan is an employee of Oxford PharmaGenesisLimited, which has received project funding from Bayer HealthCare Pharmaceuticals. Professor Beghetti has served on advisory boards/consulting for Pfizer, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, INO therapeutics, Eli Lilly, and Mondobiotech and has received lecture fees from Actelion Pharmaceuticals, Encysive, Pfizer, and Bayer HealthCare Pharmaceuticals.
For information regarding this article, E-mail: [email protected].